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PAIN
PAIN—Clinical Outcomes Studies
PPN1
ANTICIPATED PAIN PRIOR TO SURGERY COMPARED TO
ACTUAL PAIN IN PATIENTS UNDERGOING OUTPATIENT
ARTHROSCOPIC KNEE PROCEDURES
Lee WC1, Barlas S2, Gold KF1, Ma L2, Duong P2, Madoo L1, Reddy P3,
Pashos CL3
1Abt Associates Inc.—HERQuLES, Bethesda, MD, USA; 2Merck & Co.
Inc; 3Abt Associates Inc.—HERQuLES, Cambridge, MA, USA
OBJECTIVES: The objective of this analysis was to compare
anticipated pain prior to surgery with actual pain experienced
postoperatively by patients undergoing outpatient surgical
arthroscopic knee procedures. METHODS: In a prospective
multicenter study, patients undergoing knee arthroscopy
reported their anticipated pain prior to surgery. The patients
recorded actual pain at the time of discharge and on the evening
of surgery, at which time they assessed their worst pain and
average pain since the surgery. Pain was measured on a visual
analog scale (0 = none to 10 = worst pain). The anticipated pain
and actual pain were compared with a paired student t-test.
Using the difference in the actual pain and the anticipated pain
measure as a dependent variable, three multiple regressions were
performed where anticipated pain intensity, age, gender, ethnic-
ity, education, and surgery duration were used as covariates.
RESULTS: Forty-two patients enrolled in the study. The mean
age was 45.8 years, 54.8% were female, 69% were white, and
37% had a high school education or less. The mean duration of
surgery was 28 minutes. The pre-surgery anticipated pain was
6.0 + 2.1 (mean + SD); the actual pain was 2.5 + 2.8, 4.3 + 2.4
and 5.7 + 2.7 for discharge pain, average pain, and worst pain,
respectively. The t-tests indicated that discharge pain and average
pain were signiﬁcantly different from anticipated pain (p < 0.05).
On the contrary, the worst pain was in a close agreement with
the anticipated pain. From the multiple regressions, there were
no signiﬁcant covariates except the anticipated pain for the dif-
ference between discharge pain or average pain, and anticipated
pain, respectively. CONCLUSIONS: Although the worst pain
reported may be closest to the anticipated pain reported, there
is still a considerable gap in the anticipation of pain, which may
create an additional psychological burden on the patients.
PAIN
PAIN—Cost Studies
PPN2
THE DIRECT AND INDIRECT ECONOMIC IMPACT OF PAIN
AND ITS COMPARISON WITH THREE OF THE TOP FIVE MOST
COSTLY DISEASES
Trivedi DN, Grossman PR
Purdue Pharma L.P, Stamford, CT, USA
OBJECTIVES: The national estimate of total cost of illness for
pain as published by the National Institute of Health in Fiscal
year 2000 is 79 billion dollars whereby 45 billion dollars were
contributed by direct costs and 34 billion dollars by indirect
costs. Due to the prevalence and excessive cost of pain in the
United States (Gatchel R.J., 2001) it is important to estimate
current economic burden of pain on the society. This study aims
to estimate and compare direct costs and wages lost due to
missed workdays (WLMW) of pain with three of the ﬁve most
costly conditions: angina, myocardial infarction (MI), and hyper-
tension. METHODS: The self-administered questionnaire and
priority conditions supplement from 2000 Medical Expenditure
Panel Survey were used to extract 4 groups of patients (pain,
angina, MI, and hypertension). A matched sample size of 399
patients per group was identiﬁed. The costs were annualized and
are reported in dollars. Direct costs included physician, non-
physician, outpatient, inpatient, emergency room, medical sup-
plies, and home health care expenses. The WLMW were
computed using the following formula: [(Workdays lost due to
illness or stay in bed) ¥ (Hourly wages) ¥ (8)]. The analyses were
undertaken using SAS v.8.2. and Microsoft Excel 2000.
RESULTS: The results are limited to the 2000 MEPS database.
Direct cost per pain patient was $3173 as compared to $9646
for MI, $9504 for angina, and $5204 for hypertension. The
WLMW per pain patient was $210 as compared to $318 for
hypertension, $260 for MI, and $164 for angina. CONCLU-
SIONS: Pain is a costly condition. In terms of direct costs, pain
was not as costly as MI or angina. The WLMW per pain patient
was greater than angina by $46.
PPN3
AN EVALUATION OF THE DIRECT COSTS OF ADVERSE GI
EVENTS ASSOCIATED WITH THE USE OF NSAIDS IN THE
UNITED STATES
Arant TW1, Sullivan PW2
1University of Adelaide School of Medicine (Australia) and The
George Washington University, Carlsbad, CA, USA; 2University of
Colorado School of Pharmacy, Denver, CO, USA
OBJECTIVE: Non-steroidal anti-inﬂammatory drugs (NSAIDS)
are one of the most commonly prescribed classes of drugs in the
U.S. Previous studies have demonstrated that the use of NSAIDs
results in an increased risk of GI adverse events. This study seeks
to quantify the direct costs of GI-related adverse events associ-
ated with the use of non-Cox-2 selective NSAIDs. METHODS:
A decision-analytic model was used to estimate the annual direct
costs of adverse GI events from the societal perspective. We used
market share and utilization data to simulate individuals taking
prescription NSAIDS for pain in the U.S. in 2002. Univariate and
multivariate probabilistic sensitivity analyses were conducted to
examine the impact of uncertainty on the parameter estimates.
Base case estimates were derived from the published literature to
identify the attributable risk of GI-related adverse events, and
the associated treatments and costs. All costs are expressed in
2002 dollars utilizing a 3% discount rate. Incidence rates of GI
adverse events were adjusted for exposure based on actual com-
pliance with prescription NSAIDs. RESULTS: In the U.S., over
27 million patients take non-selective prescription NSAIDS for
pain. The resulting direct cost of GI-related adverse events asso-
ciated with NSAID use is approximately $567 million. CON-
CLUSIONS: Our study demonstrates that GI-related adverse
events associated with NSAID use results in substantial direct
medical costs to society each year. Total GI-related adverse event
costs associated with NSAID therapy may be reduced by
enhanced understanding of drug-speciﬁc relative risks of GI
events.
PPN4
EXAMINATION OF TOTAL HEALTH CARE EXPENDITURES
FOR PATIENTS ON LONG ACTING OPIOID MEDICATIONS
FOR THE TREATMENT OF CHRONIC PAIN IN A MEDICAID
POPULATION
Hawkins K1, Grossman P2, Orsini LS3, Ozminkowski RJ1, Baser O1
1The MEDSTAT Group, Inc, Ann Arbor, MI, USA; 2Purdue Pharma L.P;
3The Medstat Group, Inc, Cambridge, MA, USA
OBJECTIVES: To identify factors associated with total annual
health care expenditures for Medicaid patients prescribed a Long
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Acting Opioid (LAO) medication for chronic pain management.
The LAOs considered were transdermal fentanyl (TF), controlled
release morphine sulfate (CRMS) and controlled release oxy-
codone (CRO). METHODS: Medicaid beneﬁciaries from three
states during 1999–2000 were studied. Patients were followed
for at least one year, starting with their ﬁrst LAO prescription in
1999. Patients who did not have a LAO in the six months prior
to that index date were labeled “incident”, while patients with
a history of LAO use were labeled as “prevalent”. Patients were
then grouped by the opioid they received on the index date.
Disease-type, demographics, health status, health care utiliza-
tion, and expenditures were measured and compared among the
three LAO cohorts. LAO costs and total annual health care
expenditures by LAO cohort were compared using descriptive
and multivariate analyses, for the incident and prevalent patient
samples. RESULTS: Descriptive results indicate that incident (I)
and prevalent (P) LOA annual cost for CRO ($1361 I; $4146 P)
were signiﬁcantly higher than costs observed for TF ($1202 I;
$3061 P) or CRMS ($919 I; $3572 P) (p < 0.01). After control-
ling for confounding characteristics, total annual health expen-
ditures in the CRO incidence sample were similar to the CRMS
sample. However, total annual health care expenditures for the
CRO population were signiﬁcantly lower than expenditures for
the TF population, with an annual cost savings of about $960
(p < 0.01). Economic differences were not noted among the
prevalent LAO populations. CONCLUSIONS: Total cost, not
just pharmaceutical costs, should be considered when making
policy decisions about insurance coverage for LAO drugs. In the
incident sample, patients on TF cost about $960 more per year
(p < 0.01), on average, compared to similar CRMS and CRO
patients.
PPN5
AN OPIATE RENEWAL CLINIC:A COST EFFECTIVE
APPROACH TO REDUCING UNSCHEDULED PATIENT VISITS
Sampson JM, Goldenson AC, Swanson SA
VA Medical Center, Gainesville, FL, USA
OBJECTIVES: The number of patients on opiates for chronic
non-malignant pain continues to grow. With an emphasis on
treating pain, opiate medication is being used more often. Fol-
lowing patients in a Primary care clinic has become more difﬁ-
cult because of the increased time required to manage and assess
medication effects and the large number of unscheduled walk-in
visits. Our objectives were to reduce unscheduled walk-in visits,
reduce substance abuse, and diversion. METHODS: We estab-
lished a multidisciplianry opiate renewal clinic that meets once
a week and sees between 20–50 patients in a group education
setting. A thirty minute educational presentation is made each
session; all patients undergo urine drug testing and blood work.
Patients who are negative for prescribed medication receive a one
week renewal and return date to rule out diversion. Patients who
have street drugs present are referred for Substance abuse coun-
seling and given a one week renewal. Patients who are impaired
do not receive medication and appropriate referral is made.
Patients who are compliant may receive a one month renewal
and face-to-face vists every two months. RESULTS: Unscheduled
walk-in visits decreased by 76%. Referrals for substance abuse
treatment increased by 100%. It was previously difﬁcult to diag-
nose substance abuse without drug testing. Approximately 32%
of patients had positive urine for marijuana, cocaine or both.
CONCLUSIONS: An Opiate renewal clinic for patients with
chronic non-maligant pain and substance abuse can be a cost
effective approach to management.
PAIN
PAIN—Quality Of Life Studies
PPN6
RELATIONSHIP BETWEEN PAIN AND PERCEIVED 
HEALTH STATUS IN OLDER PERSONS WITH 
POST-HERPETIC NEURALGIA
Oster G1, Dukes E2, Edelsberg J1, Cleary P3
1Policy Analysis Inc. (PAI), Brookline, MA, USA; 2Pﬁzer Inc, New York,
NY, USA; 3Harvard Medical School, Boston, MA, USA
OBJECTIVE: Post-herpetic neuralgia (PHN, persistent pain fol-
lowing “shingles”) is common, especially among older persons.
The pain often lasts well beyond the acute episode, occasionally
lasting for several years. This study explored the impact of
chronic pain on perceived health status in patients with PHN.
METHODS: This was a community-based survey where persons
aged ≥65 years with PHN were recruited via advertisements in
24 large US newspapers. Eligible subjects were sent a question-
naire to complete, which included items concerning PHN pain
intensity in the prior week (current, average, worse, least), the
EQ-5D, and a 100-point global health rating scale. RESULTS:
A total of 385 persons participated in the study; 61% were age
≥75 years. Mean (±SD) current, average, worst, and least pain
due to PHN was 4.0 (±2.7), 4.6 (±2.1), 6.0 (±2.4), and 2.9 (±2.3)
respectively. Mean values for the EQ-5D weighted health index
and the global health rating scale were 0.61 (±0.26) and 65.7
(±21.1). There was a strong relationship between pain intensity
and overall health rating. Subjects with “mild” worst pain
(range: 0–4) had a mean health rating of 73.8 (±17.5), while
those with “moderate” (range: 4–<7) or “severe” (range: 7–10)
worst pain had mean values of 65.2 (±21.0) and 60.5 (±22.6)
respectively. Similar results were obtained for other measures of
pain intensity. The EQ-5D weighted health index varied in a
similar fashion in relation to pain intensity. Subjects with “mild”
average pain had a mean EQ-5D weighted health index score of
0.69 (±0.17) while those with “moderate” or “severe” average
pain had mean values of 0.58 (±0.27) and 0.25 (±0.31) respec-
tively. CONCLUSIONS: Pain intensity due to PHN is substan-
tial and has a profound impact on self-reported health.
PAIN
PAIN—Health Policy Studies
PPN7
TRENDS IN MEDICAL USE AND ABUSE OF SUSTAINED-
RELEASE OPIOID ANALGESICS: A REVISIT
Novak S1, Nemeth WC2, Lawson KA1
1University of Texas at Austin, Austin,TX, USA; 2Texas Worker’s
Compensation Commission, Austin,TX, USA
OBJECTIVES: Previous literature suggests that increases in the
medical use of opioids over the early 1990s did not contribute
to increased morbidity secondary to opioid abuse. Our objective
was to evaluate the period 1997–2001 to analyze trends in
medical use and medical abuse of three classes of opioid anal-
gesics that are commonly used in sustained-release formulations:
fentanyl, morphine, and oxycodone. METHODS: A retrospec-
tive analysis of the Drug Abuse Warning Network (DAWN) data-
base and the Automation of Reports and Consolidation Order
System (ARCOS) database for the years 1997–2001 was used
for this study. RESULTS: The analysis of the DAWN database
showed that there was an 83.5% increase in all opioid analgesic
mentions from 1997 to 2001. Mentions involving any fentanyl
compound increased 249.8%, any morphine compound
